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Congenital Zinc Deficiency from Mutations of the SLC39A4 Gene 
as the Genetic Background of Acrodermatitis Enteropathica
Acrodermatitis enteropathica (AE) is an autosomal recessive disorder with the clinical triad 
of acral dermatitis, diarrhea and alopecia. AE is known to be caused by mutations of the 
SLC39A4 gene on the chromosome band 8q24.3, encoding the zinc transporter in human. 
An 8-month-old Korean boy presented with eczematous changes on the inguinal area and 
knees and was diagnosed with AE. Blood tests revealed a markedly decreased level of 
plasma zinc, and his symptoms improved on oral zinc replacement. To confirm the 
diagnosis of AE from congenital zinc deficiency, direct sequencing analysis of SLC39A4 was 
performed and revealed that he was compound heterozygous for a known missense 
mutation (Arg95Cys) and a novel splicing mutation in the donor site of intron 7 
(c.1287+2T>C). Family study showed that his parents were heterozygous carriers of the 
mutations. To the best of our knowledge, this is the first report of genetically confirmed 
AE in Korea. 
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CASE REPORT
Pediatrics
INTRODUCTION
Acrodermatitis enteropathica (AE) is a rare autosomal recessive 
disease, which causes the classic clinical triad of acral dermati-
tis, diarrhea and alopecia (1). AE results from a defect in zinc 
absorption (1, 2), and clinical presentations can be resolved by 
oral zinc replacement. Recently, AE has been found to be caused 
by a mutation of the SLC39A4 gene, which encodes the ZIP4 
zinc transporter and is located on chromosome 8q24.3 (3-5). 
  We encountered an 8-month-old boy with acrodermatitis 
enteropathica who improved with oral zinc supplementation. 
He was confirmed to have congenital zinc deficiency by detec-
tion of a mutation of SLC39A4. We report the first case of AE 
proven by detection of a mutation of SLC39A4 in Korea. 
CASE REPORT
Clinical and biochemical analysis
An 8-month-old boy visited the dermatologic outpatient clinic 
on 6 May 2008 because of skin lesions on his inguinal area and 
knees since 7 months of age. His body weight and height were 
8.4 kg (25-50 percentile) and 69.2 cm (10-25 percentile), respec-
tively. He had shown no evidence of delay in his growth. He had 
defecated a small amount of loose stool for 3 or 4 times per day 
one month ago. His diarrhea was wax and wane and the total 
amount of stool was less than 10 g/kg/day. He had been breast 
fed up to 2 months of age, and he was being weaned at the time 
of visit. After that first visit, the patient was treated with ointment 
and oral medication for atopic dermatitis. Despite treatment, 
however, the skin lesions progressed to his cheeks, feet and scro-
tum, and were accompanied by oozing. With a presumptive di-
agnosis of AE, he was treated with oral zinc replacement (zinc 
gluconate) for 11 days. During zinc replacement, the skin lesions 
improved. At that point, we stopped the zinc replacement for 3 
weeks and considered acquired zinc deficiency. However, the 
skin lesions reappeared and progressed to erosion and eczema-
tous changes over his hands, knees, feet and perioral and ingui-
nal areas (Fig. 1). His plasma zinc level was 18.8 µg/dL (normal 
66-110 µg/dL). The zinc replacement was restarted (3 mg/kg/
day), the skin lesions improved after 1 week, and his plasma zinc 
level increased to 90.1 µg/dL. His hair growth started one month 
later. We suspected congenital zinc deficiency because of the Park C-H, et al.  •  Acrodermatitis Enteropathica Confirmed by Genetic Study
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recurrence of AE after the cessation of zinc supplementation. His 
parents are not consanguineous and have had only one baby, 
this patient. There is no family history of zinc deficiency. 
 
Genetic analysis
To confirm the diagnosis of congenital zinc deficiency, a molec-
ular genetic study on SLC39A4 was performed by direct sequenc-
ing analyses. We collected blood specimens from the proband 
and his family. Genomic DNA was isolated from leukocytes us-
ing the Wizard genomic DNA purification kit according to the 
manufacturer’s instructions (Promega, Madison, WI, USA). All 
coding exons and flanking intronic sequences of SLC39A4 were 
amplified by polymerase chain reaction (PCR) using the prim-
ers designed by the authors (available upon request) on the Ther-
mal Cycler 9700 (Applied Biosystems, Foster City, CA, USA). 
Direct sequencing was performed using the same primers for 
PCR on the BigDye Terminator Cycle Sequencing Ready Reac-
tion kit (Applied Biosystems) on the ABI Prism 3130 genetic an-
alyzer (Applied Biosystems). The sequence chromatograms ob-
tained were compared to the reference sequences (NP_570901.2 
and NM_130849.2) using the Sequencher software (Gene Codes 
Corporation, Ann Arbor, MI, USA). 
Clinical and genetic findings
We found that the patient was compound heterozygous for 2 
mutations of SLC39A4 (Fig. 2). One was a missense mutation in 
exon 2, leading to a substitution of the 95th amino acid residue 
arginine with cysteine (c.283C>T [p.Arg95Cys]). The other was 
a splice site mutation occurring in the consensus donor site of 
intron 7 (c.1287+2T>C). Family study revealed that his father 
and mother were heterozygous carriers of each mutation. 
  Currently, the patient takes oral zinc replacement (2 mg/kg/
day) and shows normal skin integrity. His plasma zinc and cop-
per levels are in the normal range. He shows normal growth and 
development.  
 
DISCUSSION
Acrodermatitis enteropathica (AE) is an inherited, rare autoso-
mal recessive disease, with an estimated incidence of 1 per 
500,000 children without predilection for race or sex (6). The 
high rate of consanguineous marriages in some cohorts leads 
to a higher carrier state of the mutation (1:50) (7).
  Clinical manifestations of AE include characteristic skin le-
sions, such as acral and periorificial erythematous, scaly plaques 
with crusts and ulcerations, diarrhea, alopecia, growth failure 
and delayed puberty (1, 2). AE-like skin eruptions can be devel-
oped by dietary zinc deficiency; these can be resolved by oral 
zinc replacement and do not recur (8). However, AE usually re-
curs after ceasing the supply of zinc (2). 
  At first, this patient was misdiagnosed with atopic dermatitis 
because of eczematous changes of his inguinal area and knees. 
After applying steroids, the lesions did not improve and had 
even progressed. We reassessed him as having dietary zinc de-
ficiency and administered oral zinc gluconate. After 10 days, the 
skin lesions disappeared, and he had a good appetite and was 
well nourished. As a result, we stopped zinc replacement. How-
ever, his skin lesions relapsed and became aggravated within one 
month after cessation of the zinc. We then considered congeni-
tal zinc deficiency and checked for the mutation of SLC39A4. 
Fig. 1. An 8-month-old boy with erythematous and desquamated skin lesions around 
knees, feet, and perioral and inguinal areas.
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Fig. 2. Direct sequencing analyses of the SLC39A4 gene. The proband was compound 
heterozygous for a previously reported missense mutation c.283C>T (p.Arg95Cys) 
and a novel splicing mutation in the donor site of intron 7, c.1287+2T>C. The parents 
were heterozygous carriers of the mutations.Park C-H, et al.  •  Acrodermatitis Enteropathica Confirmed by Genetic Study
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  Acrodermatitis enteropathica (AE) was first named in 1943 (9), 
and its pathogenesis was discovered in 1973 (2). In 2001, Wang 
et al. found the location of the AE gene on chromosome 8q24.3 
by homozygosity mapping (3). In 2002, the defected gene was 
identified as SLC39A4 (for solute carrier family 39, member 4), 
which was known to encode the zinc/iron-regulated transport-
er-like protein (ZIP4) zinc transporter that included zinc-uptake 
proteins (4, 5). This gene is expressed in parts of the intestine, 
including the duodenum and jejunum, which are essential sites 
of zinc absorption. The protein product of SLC39A4 is dynami-
cally regulated by zinc (4). 
  Molecular genetic studies revealed that our patient was het-
erozygous for 2 mutations in the SLC39A4 gene. SLC39A4 is com-
posed of 12 exons, encoding a protein of 647 amino acids (MIM# 
607059). The Human Genome Mutation Database shows 25 dif-
ferent mutations in SLC39A4, including 15 missense mutations 
and 2 splicing mutations (Ref: http://www.hgmd.cf.ac.uk/ac/gene. 
php?gene=SLC39A4). A recent report described other novel mu-
tations and unclassifiable variations (10). Since most SLC39A4 
mutations are private and occur in different types and over the 
entire gene, direct sequencing of all coding exons and flanking 
intronic sequences is the molecular diagnostic approach of choice 
in AE. The missense mutation in our patient, Arg95Cys, was pre-
viously reported by Nakano et al. (11) in a Japanese family with 
AE. Based on the observation that Arg95Cys was not occurring 
in 100 control chromosomes screened, they concluded that Ar-
g95Cys was a disease-causing mutation. The precise functional 
implication of the Arg95 residue, however, needs to be deter-
mined (11). The other mutation, c.1287+2T>C, was a novel splic-
ing mutation in the donor site of intron 7, following 2 mutations 
in acceptor sites of introns 2 and 6 found in the literature (11). 
Family study revealed that each of the mutations had been in-
herited from his parents, compatible with the autosomal reces-
sive inheritance pattern of the disease. Partly due to the limited 
number of mutations reported thus far, no genotype-phenotype 
correlations have been reported in SLC39A4-related AE (10).
  The treatment of AE is simple; only oral zinc replacement is 
needed (12). Zinc replacement therapy in AE should be started 
at 3 mg/kg/day of elemental zinc (12). Serum or plasma zinc 
levels and zinc-dependant enzyme levels should be monitored 
every 3 or 6 months (12). In addition, the copper level must be 
monitored, because zinc supplementation usually reduces cop-
per absorption (12). The copper level in this case was within nor-
mal limits, 114.2 µg/dL (normal range, 75-145 µg/dL). 
  In summary, patients with relapsed nutritional AE after ceas-
ing zinc supplemention should be tested for SLC39A4 gene mu-
tations to confirm congenital zinc deficiency. We report the first 
case of congenital AE confirmed by molecular genetic study with 
a novel splicing mutation in the donor site of intron 7.
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